Evogene to Showcase Innovative ChemPass AI Strategy at H.C. Wainwright Global Conference

Evogene Ltd., a prominent player in computational biology and chemistry, is gearing up for a significant appearance at the H.C. Wainwright 27th Annual Global Investment Conference scheduled to take place from September 8 to September 10, 2025, in New York. Ofer Haviv, the President and CEO of Evogene, will represent the company, highlighting its strategic focus on leveraging its unique technology platform, ChemPass AI.

A Highlight on ChemPass AI

Evogene’s ChemPass AI is a proprietary generative AI engine designed specifically for the discovery and optimization of small molecules pivotal in both pharmaceutical and agricultural sectors. This innovative tool plays a crucial role in designing unique and highly effective small molecules, which are essential for addressing the ongoing challenges in drug development and agricultural improvements.

During the conference, Mr. Haviv’s presentation will delve into how this advanced technology not only maximizes the potential of existing compounds but also reduces the time and costs associated with the development cycles, ultimately enhancing the probability of successful outcomes.

One-on-One Engagements

In addition to his main presentation on September 10, Mr. Haviv will also be available for individual meetings with interested investors and representatives from various companies at the conference. This offers a unique opportunity for attendees to engage directly with Evogene's leadership team and explore synergies that could foster future collaborations.

About Evogene Ltd.

Established with the vision to revolutionize product development in the life sciences, Evogene Ltd. is at the forefront of AI-driven discovery and development. The company is committed to inventing next-generation small molecules that can make a substantial impact on the pharmaceutical and ag-chemical industries. By harnessing the power of the ChemPass AI tech engine, Evogene aims to tackle pressing issues related to small molecule discovery and optimization. This strategic approach is not only about innovation but also focuses on building meaningful partnerships and collaborations to create value across the industry.

With its novel acquisition of generative AI capabilities, Evogene is well-positioned to lead advancements in small molecules aimed at solving critical health and food supply challenges. The conference is expected to be a pivotal moment for the company as it shares insights into its strategy for the future.

For those interested in learning more about Evogene’s innovative approaches and its impact on the industry, the company’s official website provides a wealth of information and resources.

Conclusion

The H.C. Wainwright Global Investment Conference is an excellent platform for Evogene to showcase its innovative strategies and the potential of its ChemPass AI technology in reshaping the landscape of small molecule development. As Mr. Haviv prepares to take the stage, the anticipation builds for what this pioneering approach will mean for the future of pharmaceutical and agricultural advancements.